Futibatinib for treating cholangiocarcinoma with FGFR2 gene rearrangements

Futibatinib is currently in clinical development for treating relapsed or refractory advanced cholangiocarcinoma (CCA) with fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement.
CCA, also known as bile duct cancer, is a rare disease in which malignant cells are formed in the bile duct. FGFRs are receptor enzymes that are involved in several biological process such as tissue repair. Alterations in FGFRs can lead to the development or progression of cancer. CCA symptoms are usually hard to spot but could include itchy skin, darker urine, pale stool, loss of appetite, chronic fatigue, high temperature and shivering. The causes of CCA remain unknown. However, adults aged 65 and older are reported to have an increased risk of developing the disease. There remains a need for potent FGFR inhibitors that are less susceptible to drug resistance.